TORONTO, ONTARIO--(Marketwired - Feb 13, 2014) - BioSyent Inc. ("BioSyent") (TSX VENTURE:RX) announced today that it has again been named as one of the TSX Venture Top 50 companies.
The 2014 TSX Venture 50 is an annual ranking of strong performing companies listed on the TSX Venture Exchange. The TSX Venture 50 includes the top 10 companies in five major industry sectors that have been identified as leaders in Canada's public venture market. BioSyent is ranked on the list of ten leading Technology and Life Sciences companies for the year. Companies are selected based on four equally weighted criteria - return on investment, trading activity, market capitalization growth, and analyst coverage. The results were obtained from data to December 31, 2013.
BioSyent is the only TSX Venture Company ranked as a top performer in each of 2012, 2013, and 2014.
"With more than 2,100 companies listed on the TSX Venture Exchange, it is a testament to the performance of our team to have BioSyent named for three consecutive years as one of the TSX Venture Top 50 companies," said René Goehrum, President and CEO of BioSyent Inc. "Our business has progressed dramatically since we were named to the 2012 TSX Venture 50. Being named again to the TSX Venture 50 is recognition by investors that we have an effective strategy and that we have been consistently effective in executing that strategy."
For a direct market quote (15 minute delay) for the TSX Venture Exchange and other company financial information please visit www.tmxmoney.com.
About BioSyent Inc.
Listed on the Toronto Venture Exchange under the trading symbol "RX", BioSyent is a profitable growth oriented specialty pharmaceutical company which searches the globe to in-license or acquire innovative pharmaceutical products that have been successfully developed, are safe and effective, and have a proven track record of improving the lives of patients and supporting the healthcare professionals that treat them.
Once a product of interest has been found, BioSyent then acquires the exclusive rights to the product and manages it through the Canadian governmental regulatory approval process. Once approved, BioSyent markets the product throughout Canada.
At the date of this press release the company had 13,626,195 shares issued and outstanding.
This press release may contain information or statements that are forward-looking. The contents herein represent our judgment, as at the release date, and are subject to risks and uncertainties that may cause actual results or outcomes to be materially different from the forward-looking information or statements. Potential risks may include, but are not limited to, those associated with clinical trials, product development, future revenue, operations, profitability and obtaining regulatory approvals.
The TSX Venture Exchange assumes no responsibility for the accuracy of this release and neither approves nor disapproves of the same.